The National Institute for Health and Clinical Excellence (NICE) has not recommended Lucentis for the treatment of diabetic macular oedema (DME) for the English and Welsh NHS.
Lucentis not recommended by NICE for treating DME in England and Wales
The National Institute for Health and Clinical Excellence (NICE) has not recommended Lucentis for the treatment of diabetic macular oedema (DME for the English and Welsh NHS.
Novartis submitted present clinical data and information on NHS ophthalmologists on the realistic uses of Lucentis (ranibizumab).
NICE has recognized the benefits of Lucentis in that it prevents the production of endothelial growth factor (VEGF). But it has concluded that the cost effectiveness model does not reflect expected clinical practice.
Sir Andrew Dillon, Chief Executive at NICE said: "NICE already recommends ranibizumab for wet age-related macular degeneration, and although it has been shown in clinical trials to be an effective treatment for DME, the Appraisal Committee was unable to recommend the drug as a cost-effective use of NHS resources compared to laser photocoagulation for this condition."
Laser treatment is currently the top treatment for DME patients but there are, at present, no other licensed medical treatment options.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.